Avastin To Be Standard Add-On Agent In Colorectal Cancer, Genentech Says

Genentech believes that its investigational agent Avastin will become standard add-on therapy to chemotherapy in the treatment of colorectal cancer after unveiling data demonstrating that the VEGF inhibitor "markedly" improves survival in first-line metastatic disease